ErbB-2, also known as human epidermal growth factor receptor 2 (HER2), cluster of differentiation 340 (CD340), proto-oncogene Neu, is encoded by the ERBB2 gene. As a member of the human epidermal growth factor receptor (HER/EGFR/ERBB) family, ErbB2 has become an important biomarker and target of therapy for breast cancer. Not only the overexpression of ErbB2 occurs in breast cancer, but also it is strongly associated with the ovarian cancer, stomach cancer, lung adenocarcinoma, uterine cancer, salivary gland cancer, acute lymphoblastic leukemia (ALL), bladder cancer, childhood medulloblastoma, colorectal cancer, oral squamous cell carcinoma, germ-cell testicular tumor, cholangiocarcinoma, osteosarcoma, pancreatic adenocarcinoma and prostate cancer.
CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | Inquiry & Datasheet |
CAR-T-1-L337-2 | Anti-ErbB2 scFv h(CD28) CART, pCDCAR1 | Human | OTI5C4 | Mouse | scFv-CD28 | Lentiviral | T cell | |
CAR-T-1-L337-G | Anti-ErbB2 scFv h(FcεRIγ) CART, pCDCAR1 | Human | OTI5C4 | Mouse | scFv-FcεRIγ | Lentiviral | T cell | |
CAR-T-1-L337-Z | Anti-ErbB2 scFv h(CD3ζ) CART, pCDCAR1 | Human | OTI5C4 | Mouse | scFv-CD3ζ | Lentiviral | T cell | |
CAR-T-2-L337-2G | Anti-ErbB2 scFv h(CD28-FcεRIγ) CART, pCDCAR1 | Human | OTI5C4 | Mouse | scFv-CD28-FcεRIγ | Lentiviral | T cell | |
CAR-T-2-L337-2Z | Anti-ErbB2 scFv h(CD28-CD3ζ) CART, pCDCAR1 | Human | OTI5C4 | Mouse | scFv-CD28-CD3ζ | Lentiviral | T cell | |
CAR-T-2-L337-4G | Anti-ErbB2 scFv h(CD4-FcεRIγ) CART, pCDCAR1 | Human | OTI5C4 | Mouse | scFv-CD4-FcεRIγ | Lentiviral | T cell | |
CAR-T-2-L337-4Z | Anti-ErbB2 scFv h(CD4-CD3ζ) CART, pCDCAR1 | Human | OTI5C4 | Mouse | scFv-CD4-CD3ζ | Lentiviral | T cell | |
CAR-T-2-L337-8Z | Anti-ErbB2 scFv h(CD8-CD3ζ) CART, pCDCAR1 | Human | OTI5C4 | Mouse | scFv-CD8-CD3ζ | Lentiviral | T cell | |
CAR-T-2-L337-BZ | Anti-ErbB2 scFv h(41BB-CD3ζ) CART, pCDCAR1 | Human | OTI5C4 | Mouse | scFv-41BB-CD3ζ | Lentiviral | T cell | |
CAR-T-2-L337-CZ | Anti-ErbB2 scFv h(b2c-CD3ζ) CART, pCDCAR1 | Human | OTI5C4 | Mouse | scFv-b2c-CD3ζ | Lentiviral | T cell | |
CAR-T-3-L337-2BZ | Anti-ErbB2 scFv h(CD28-41BB-CD3ζ) CART, pCDCAR1 | Human | OTI5C4 | Mouse | scFv-CD28-41BB-CD3ζ | Lentiviral | T cell | |
CAR-T-3-L337-2XZ | Anti-ErbB2 scFv h(CD28-OX40-CD3ζ) CART, pCDCAR1 | Human | OTI5C4 | Mouse | scFv-CD28-OX40-CD3ζ | Lentiviral | T cell | |
CAR-NK-1-M331-2 | Anti-ErbB2 scFv h(CD28) CARNK, pCDCAR1 | Human | FRP5 | Rabbit | scFv-CD28 | Lentiviral | NK cell | |
CAR-NK-1-M331-G | Anti-ErbB2 scFv h(FcεRIγ) CARNK, pCDCAR1 | Human | FRP5 | Rabbit | scFv-FcεRIγ | Lentiviral | NK cell | |
CAR-NK-1-M331-Z | Anti-ErbB2 scFv h(CD3ζ) CARNK, pCDCAR1 | Human | FRP5 | Rabbit | scFv-CD3ζ | Lentiviral | NK cell | |
CAR-NK-2-M331-2Z | Anti-ErbB2 scFv h(CD28-CD3ζ) CARNK, pCDCAR1 | Human | FRP5 | Rabbit | scFv-CD28-CD3ζ | Lentiviral | NK cell | |
CAR-NK-2-M331-4G | Anti-ErbB2 scFv h(CD4-FcεRIγ) CARNK, pCDCAR1 | Human | FRP5 | Rabbit | scFv-CD4-FcεRIγ | Lentiviral | NK cell | |
CAR-NK-2-M331-4Z | Anti-ErbB2 scFv h(CD4-CD3ζ) CARNK, pCDCAR1 | Human | FRP5 | Rabbit | scFv-CD4-CD3ζ | Lentiviral | NK cell | |
CAR-NK-2-M331-8Z | Anti-ErbB2 scFv h(CD8-CD3ζ) CARNK, pCDCAR1 | Human | FRP5 | Rabbit | scFv-CD8-CD3ζ | Lentiviral | NK cell | |
CAR-NK-2-M331-BG | Anti-ErbB2 scFv h(CD28-FcεRIγ) CARNK, pCDCAR1 | Human | FRP5 | Rabbit | scFv-CD28-FcεRIγ | Lentiviral | NK cell | |
CAR-NK-2-M331-BZ | Anti-ErbB2 scFv h(41BB-CD3ζ) CARNK, pCDCAR1 | Human | FRP5 | Rabbit | scFv-41BB-CD3ζ | Lentiviral | NK cell | |
CAR-NK-2-M331-CZ | Anti-ErbB2 scFv h(b2c-CD3ζ) CARNK, pCDCAR1 | Human | FRP5 | Rabbit | scFv-b2c-CD3ζ | Lentiviral | NK cell | |
CAR-NK-3-M331-2BZ | Anti-ErbB2 scFv h(CD28-41BB-CD3ζ) CARNK, pCDCAR1 | Human | FRP5 | Rabbit | scFv-CD28-41BB-CD3ζ | Lentiviral | NK cell | |
CAR-NK-3-M331-2XZ | Anti-ErbB2 scFv h(CD28-OX40-CD3ζ) CARNK, pCDCAR1 | Human | FRP5 | Rabbit | scFv-CD28-OX40-CD3ζ | Lentiviral | NK cell | |
CAR-T-2-M550-BZ | Anti-HER2 VHH h(41BB-CD3ζ) CAR, [T] | Human | Camelid | VHH-41BB-CD3ζ | Lentiviral | T cell | ||
CAR-T-2-M550-CZ | Anti-HER2 VHH h(b2c-CD3ζ) CAR, [T] | Human | Camelid | VHH-b2c-CD3ζ | Lentiviral | T cell | ||
CAR-T-1-M550-2 | Anti-HER2 VHH h(CD28) CAR, [T] | Human | Camelid | VHH-CD28 | Lentiviral | T cell | ||
CAR-T-3-M550-2BZ | Anti-HER2 VHH h(CD28-41BB-CD3ζ) CAR, [T] | Human | Camelid | VHH-CD28-41BB-CD3ζ | Lentiviral | T cell | ||
CAR-T-2-M550-2Z | Anti-HER2 VHH h(CD28-CD3ζ) CAR, [T] | Human | Camelid | VHH-CD28-CD3ζ | Lentiviral | T cell | ||
CAR-T-2-M550-2G | Anti-HER2 VHH h(CD28-FcεRIγ) CAR, [T] | Human | Camelid | VHH-CD28-FcεRIγ | Lentiviral | T cell | ||
CAR-T-3-M550-2XZ | Anti-HER2 VHH h(CD28-OX40-CD3ζ) CAR, [T] | Human | Camelid | VHH-CD28-OX40-CD3ζ | Lentiviral | T cell | ||
CAR-T-1-M550-Z | Anti-HER2 VHH h(CD3ζ) CAR, [T] | Human | Camelid | VHH-CD3ζ | Lentiviral | T cell | ||
CAR-T-2-M550-4Z | Anti-HER2 VHH h(CD4-CD3ζ) CAR, [T] | Human | Camelid | VHH-CD4-CD3ζ | Lentiviral | T cell | ||
CAR-T-2-M550-4G | Anti-HER2 VHH h(CD4-FcεRIγ) CAR, [T] | Human | Camelid | VHH-CD4-FcεRIγ | Lentiviral | T cell | ||
CAR-T-2-M550-8Z | Anti-HER2 VHH h(CD8-CD3ζ) CAR, [T] | Human | Camelid | VHH-CD8-CD3ζ | Lentiviral | T cell | ||
CAR-MZ019 | Anti-ErbB2 (Trastuzumab) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | Trastuzumab | Humanized | scFv-CD28-CD3ζ | Lentiviral | T cell | |
CAR-MZ029 | Anti-ErbB2 (C6-B1D2) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | C6-B1D2 | Human | scFv-CD28-CD3ζ | Lentiviral | T cell | |
CAR-MZ030 | Anti-ErbB2 (C6MH3-B1) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | C6MH3-B1 | Human | scFv-CD28-CD3ζ | Lentiviral | T cell | |
CAR-MZ031 | Anti-ErbB2 (C6ML3-9) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | C6ML3-9 | Human | scFv-CD28-CD3ζ | Lentiviral | T cell | |
CAR-MZ032 | Anti-ErbB2 (C6.5) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | C6.5 | Human | scFv-CD28-CD3ζ | Lentiviral | T cell | |
CAR-ZP8499 | A uniCAR [Anti-CD16A CAR], with a mAb-based CAR Adaptor [Anti-ErbB2 (Herceptin)], a Switchable CAR System | Breast cancer | Lentiviral vector |
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.
LEARN MOREAngiotensin-converting Enzyme 2 (ACE2)-CHO Cell Line Model for COVID-19: Helps researchers to further study the interaction between the receptor ACE2 and the COVID-19 virus.
LEARN MORETRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.
LEARN MOREThe latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE